Results 161 to 170 of about 171,997 (216)

C-type lectin-like receptor 2 in platelets amplifies inflammation in rheumatoid arthritis. [PDF]

Res Pract Thromb Haemost
Sasaki T, Golebiewska E, Shirai T, Tsukiji N, Koyama K, Tamura S, Otake S, Osada M, Haro H, Ozaki Y, Suzuki-Inoue K.   +10 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

MGL/CLEC10A is an important C-type lectin receptor activated in the innate immune response to <i>Mycobacterium tuberculosis</i> and is suppressed in people with HIV. [PDF]

Front Immunol
Browning SE, Bharaj P, Fan X, Nguyen H, Holloway AJ, Naqvi KF, Lisinicchia JG, Paez RN, Chauhan S, Huante MB, Martinez-Martinez YB, Endsley MA, Gelman BB, Endsley JJ.   +13 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor. [PDF]

Breast Cancer
Yamaguchi-Tanaka M, Kurihara Y, Takagi K, Sato A, Yasuda I, Yamazaki Y, Miyashita M, Suzuki T.   +7 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach. [PDF]

Front Bioeng Biotechnol
Chen Y, Li Q, Lou S, Zeng H, Chen S.
europepmc   +1 more source

Adding Intratumoral Antibody‐Photoabsorber Conjugate Improves Efficacy of Near‐Infrared Photoimmunotherapy (NIR‐PIT)

Cancer Science, EarlyView.
Intravenous (IV) or intratumoral (IT) cetuximab distribution in A431 tumor (essence of Figure 2). ABSTRACT Near‐infrared photoimmunotherapy (NIR‐PIT) is a new type of cancer treatment that specifically kills target cells while sparing normal tissue. This treatment induces cancer cell death by activating a photoreactive dye with near‐infrared light in ...
Miyu Kano, Aki Furusawa, Seiichiro Takao, Makoto Kano, Motofumi Suzuki, Hiroshi Yamamoto, Shuhei Okuyama, Ko Kitamura, Peter L. Choyke, Hisataka Kobayashi   +9 more
wiley   +1 more source

Evaluation of the podoplanin/C-type lectin-like receptor-2 (CLEC-2) pathway as a mediator of platelet and coagulation activation in sickle cell disease. [PDF]

Res Pract Thromb Haemost
Borba-Junior IT, Barbosa MDS, Moraes CRP, Silva LQ, Santos I, Benites B, Annichino-Bizzacchi JM, Costa FF, De Paula EV.   +8 more
europepmc   +1 more source